522 Results

People

  1. De Angelis
    De Angelis
  2. Kris
    Kris
  3. Motzer
    Motzer
  4. Livingston
    Livingston
  5. Aghajanian
    Aghajanian
  6. Krown
    Krown
  7. Panageas
    Panageas
  8. Miller
    Miller
  9. Tyson
    Tyson
  10. Vickers
    Vickers

Groups

  1. Department of Medicine (289)
  2. Solid Tumor Oncology Division (180)
  3. Hematologic Malignancies, Division of (104)
  4. Center for Hematologic Malignancies (92)
  5. Survivorship Research (61)
  6. GSK Faculty (55)
  7. Tow Center for Developmental Oncology (TCDO) (51)
  8. Epidemiology and Biostatistics (49)
  9. Population Sciences Research Program (45)
  10. Genitourinary Oncology Service (41)
  1. "headache"
Formats
  1. Journal Article (491)
  2. Review (17)
  3. Research Letter (5)
  4. Conference Paper (3)
  5. Editorial (3)
  6. Book Whole (1)
  7. Guidelines (1)
  8. Miscellaneous (1)
Groups
  1. Department of Medicine (289)
  2. Solid Tumor Oncology Division (180)
  3. Hematologic Malignancies, Division of (104)
  4. Center for Hematologic Malignancies (92)
  5. Survivorship Research (61)
  6. GSK Faculty (55)

More Groups

People
  1. Lisa De Angelis (20)
  2. Mark Kris (20)
  3. Robert Motzer (19)
  4. Philip Livingston (13)
  5. Carol Aghajanian (12)
  6. Katherine Panageas (12)

More People

Years
  1. 2025 (15)
  2. 2024 (34)
  3. 2023 (30)
  4. 2022 (16)
  5. 2021 (18)
  6. 2020 (35)

More Years

Publications
  1. Journal of Clinical Oncology (37)
  2. Clinical Cancer Research (23)
  3. Lancet Oncology (20)
  4. Blood (18)
  5. New England Journal of Medicine (17)
  6. Cancer (16)

More Publications

Publishers
  1. Elsevier Inc. (68)
  2. Elsevier Science, Inc. (43)
  3. Springer (42)
  4. American Society of Clinical Oncology (37)
  5. Nature Publishing Group (32)
  6. Oxford University Press (29)

More Publishers

Results (522)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
    Journal Article

    Roddie, C.; Lekakis, L. J.; Marzolini, M. A. V.; Ramakrishnan, A.; Zhang, Y.; Hu, Y.; Peddareddigari, V. G. R.; Khokhar, N.; Chen, R.; Basilico, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL
    Journal Article

    Ruan, J.; Moskowitz, A.; Mehta-Shah, N.; Sokol, L.; Chen, Z.; Kotlov, N.; Nos, G.; Sorokina, M.; Maksimov, V.; Sboner, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
    Journal Article

    Issa, G. C.; Aldoss, I.; DiPersio, J.; Cuglievan, B.; Stone, R.; Arellano, M.; Thirman, M. J.; Patel, M. R.; Dickens, D. S.; Shenoy, S.; more...
    Nature (2023)

    Fulltext@MSK | Save
  • Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: A phase 1, dose-finding and expansion study
    Journal Article

    Garcia-Manero, G.; Goldberg, A. D.; Winer, E. S.; Altman, J. K.; Fathi, A. T.; Odenike, O.; Roboz, G. J.; Sweet, K.; Miller, C.; Wennborg, A.; more...
    The Lancet Haematology (2023)

    Fulltext@MSK | Save
  • Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
    Journal Article

    Motzer, R. J.; Hutson, T. E.; Tomczak, P.; Michaelson, M. D.; Bukowski, R. M.; Oudard, S.; Negrier, S.; Szczylik, C.; Pili, R.; Bjarnason, G. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: Longer-term follow-up of ASCEMBL
    Journal Article

    Hochhaus, A.; Réa, D.; Boquimpani, C.; Minami, Y.; Cortes, J. E.; Hughes, T. P.; Apperley, J. F.; Lomaia, E.; Voloshin, S.; Turkina, A.; more...
    Leukemia (2023)

    Fulltext@MSK | Save
  • Clinical outcomes and toxicities of 100 patients treated with proton therapy for chordoma on the proton collaborative group prospective registry
    Journal Article

    Chhabra, A. M.; Rice, S. R.; Holtzman, A.; Choi, J. I.; Hasan, S.; Press, R. H.; Chang, J.; Halasz, L.; Tsai, H. K.; Wang, C. J.; more...
    Radiotherapy and Oncology (2023)

    Fulltext@MSK | Save
  • Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): A double-blind, randomised, phase 3 trial
    Journal Article

    Motzer, R. J.; Russo, P.; Grünwald, V.; Tomita, Y.; Zurawski, B.; Parikh, O.; Buti, S.; Barthélémy, P.; Goh, J. C.; Ye, D.; more...
    Lancet (2023)

    Fulltext@MSK | Save
  • Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer
    Review

    Yang, J. C. H.; Zhou, C.; Jänne, P. A.; Ramalingam, S. S.; Kim, T. M.; Riely, G. J.; Spira, A. I.; Piotrowska, Z.; Mekhail, T.; Garcia Campelo, M. R.; more...
    Expert Review of Anticancer Therapy (2023)

    Fulltext@MSK | Save
  • ALK-positive histiocytosis: A new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition
    Journal Article

    Kemps, P. G.; Picarsic, J.; Durham, B. H.; Hélias-Rodzewicz, Z.; Hiemcke-Jiwa, L.; van den Bos, C.; van de Wetering, M. D.; van Noesel, C. J. M.; van Laar, J. A. M.; Verdijk, R. M.; more...
    Blood (2022)

    Fulltext@MSK | Save